This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Elizabeth N. Dupras
Senior Director, Regulatory Science
Elizabeth N. Dupras (Beth) has more than 30 years of pharmaceutical industry experience. Beth has expertise in CM&C technical writing, analytical development and an excellent working knowledge of FDA regulations, ICH guidelines and current Good Manufacturing Practices. Beth has a working knowledge of document/data management systems and eCTD submission management/publishing systems.
Beth specializes in assessing CM&C documentation for all phases of both development and post‑marketing life cycle management, as well as writing the Quality documentation required for submission to Health Authorities. In addition, Beth has substantial experience in assessing general regulatory, nonclinical and clinical documentation in support of global regulatory submissions. She has coordinated the submissions and responses to queries from regulatory health authorities resulting in approval of applications.
Beth has extensive experience in preparing meeting requests and briefing packages, coordinating rehearsals and attending FDA/Sponsor pre-IND, EOP2, pre-NDA, and Type C/Type D Guidance meetings. She interacts with FDA as US agent on behalf of multiple clients.
Beth is a Regulatory Affairs Certified (RAC) professional and holds a bachelor’s degree in chemistry from St. Bonaventure University, St. Bonaventure, NY. Beth is a member of the Regulatory Affairs Professionals Society (RAPS) and the Drug Information Association (DIA).
Beth is an energetic advocate and fundraiser for breast cancer awareness and research. In particular, Beth has participated in the Susan G. Komen 3-Day, a 60-mile walk (participants walk 20 miles a day for 3 days). The 3-Day has raised over $800 million for breast cancer awareness, community outreach (screening and treatment) and research. Beth is participated in her fourth 3‑Day in 2018 and was welcomed as a member of the 3‑Day Commitment Club for her ongoing support of this event.